Our current clinical trial (“CAR T cells for HIV infection”, NCT04648046) is designed to investigate anti-HIV duoCAR T cell therapy as a potential HIV remission strategy, using ART interruption to enable reactivation of latent reservoir cells and increased HIV-1 Env expression on their surface to render them susceptible to CAR-mediated elimination. Here, ERVW-1 is linked to HIV infectious disease.